HK$15.85
4.35%
Hong Kong, Oct 02, 04:08 pm HKT. Closed.
ISIN
KYG8875G1029
Symbol
1530

3sbio Inc Stock price

HK$16.57
+0.45 2.79% 1M
-7.71 31.75% 6M
-7.61 31.47% YTD
-13.43 44.77% 1Y
+10.02 152.98% 3Y
+8.92 116.60% 5Y
+7.79 88.72% 10Y
+7.22 77.22% 20Y
Hong Kong, Closing price Wed, Sep 30 2026
+0.65 4.08%
ISIN
KYG8875G1029
Symbol
1530
Industry

Is 3sbio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$42.1b
Enterprise Value
HK$22.5b
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
4.4
P/S | estimate
2.0 | 3.7
EV/Sales | estimate
1.1 | 2.0
EV/FCF | ex SBC
2.1 | 2.1
P/B
1.3
Dividends
DPS
HK$0.25
Yield 1Y | 5Y
1.5% | 1.7%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
6.2% | 10.4%
Increased
0 Years
Financials
Revenue | estimate
HK$20.9b | HK$11.3b
EBITDA
-
EBIT
HK$12.7b
Net Income
HK$9.7b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
96.9% | -45.6%
EBITDA
-
EBIT
336.9%
Net Income
250.7%
Free Cash Flow
-
Margin
Gross
91.9%
EBITDA
-
EBIT
60.9%
Net
46.3%
Free Cash Flow | ex SBC
- | -
Financial Health
Equity Ratio
75.1%
Return on Equity
31.2%
ROCE
34.2%
ROIC
59.2%
Debt/Equity
-
More
EPS
HK$3.7
FCF per Share
-
Short interest
-
Employees
6k
Rev per Employee
HK$3.4m

3sbio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a 3sbio Inc forecast:

19x Buy
90%
2x Hold
10%

Analyst Opinions

21 Analysts have issued a 3sbio Inc forecast:

Buy
90%
Hold
10%

Financial data from 3sbio Inc

Jun '26
+/-
%
20,908 20,908
97% 97%
100%
- Direct Costs 1,685 1,685
9% 9%
8%
19,223 19,223
112% 112%
92%
- Selling and Administrative Expenses 4,495 4,495
3% 3%
21%
- Research and Development Expense 1,939 1,939
19% 19%
9%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 12,723 12,723
337% 337%
61%
Net Profit 9,679 9,679
251% 251%
46%

In millions HKD.

Don't miss a Thing! We will send you all news about 3sbio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

3SBio, Inc. operates as an investment holding company, which engages in the development, production, marketing, and sale of biopharmaceutical products. The company is headquartered in Shenyang, Liaoning and currently employs 6,268 full-time employees. The company went IPO on 2015-06-11. The firm's main products include biopharmaceuticals such as TPIAO, EPIAO, Yisaipu, and Cipterbin, as well as small moleculessuch as Mandi and Remitch. The firm is also engaged in the contract development and manufacturing operations (CDMO) business that provides customers with research, development and production of a variety of biopharmaceuticals and therapeutic technology platform services. The firm's products are mainly used for chemotherapy-induced thrombocytopenia (CIT), anemia caused by chronic kidney disease (CKD), treatment of chemotherapy-induced anemia (CIA), ankylosing spondylitis (AS) and psoriasis. The firm mainly operates its businesses in the domestic and overseas markets.

Head office Cayman Islands
CEO Mr. Lou
Employees 6,109
Website www.3sbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today